ethyl 3-(4-hydroxyphenyl)-2-nitro-5-oxo-5-phenyl-pentanoate

• 分子结构分类: 有机化合物 - 木脂素、新木脂素和相关化合物
• 英文名称: ethyl 3-(4-hydroxyphenyl)-2-nitro-5-oxo-5-phenyl-pentanoate
• 英文别名: Ethyl 3-(4-hydroxyphenyl)-2-nitro-5-oxo-5-phenyl-pentanoate；ethyl 3-(4-hydroxyphenyl)-2-nitro-5-oxo-5-phenylpentanoate
• 化学式: C₁₉H₁₉NO₆
• 分子量: 357.363
• InChiKey: SZEZIVYAUNFVDB-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.2
• 重原子数：
  26
• 可旋转键数：
  8
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.26
• 拓扑面积：
  109
• 氢给体数：
  1
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  ethyl 3-(4-hydroxyphenyl)-2-nitro-5-oxo-5-phenyl-pentanoate 在 N-甲基吗啉 、 ammonium acetate 、 sodium methylate 、 1-羟基苯并三唑 、 溶剂黄146 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 、 三乙胺 、 sodium hydroxide 作用下， 以 甲醇 、 乙二醇二甲醚 、 乙醇 、 水 、 N,N-二甲基甲酰胺 为溶剂， 反应 103.08h， 生成 methyl 6-[3-(4-hydroxyphenyl)-5-phenyl-1H-pyrrole-2-carboxamido] hexanoate
  参考文献：
  名称：

  [EN] HYDROXYPHENYL PYRROLE COMPOUNDS CONTAINING AN HYDROXAMIC ACID AS HDAC INHIBITORS AND MEDICINAL APPLICATIONS THEREOF
  [FR] COMPOSÉS HYDROXYPHÉNYL-PYRROLE CONTENANT UN ACIDE HYDROXAMIQUE, UTILISABLES EN TANT QU'INHIBITEURS DE HDAC ET LEURS APPLICATIONS MÉDICALES

  摘要：

  本发明涉及源自羟基苯基1H-吡咯环的化合物，其具有以下结构式（I）：以及它们的制备方法，包括相同的药物组合物，以及它们用于治疗和/或预防由组蛋白去乙酰化酶介导的疾病，如癌症、血液系统恶性肿瘤、自身免疫疾病、炎症性疾病、中枢神经系统疾病（如神经退行性疾病和精神障碍）、心血管疾病、内分泌和代谢紊乱，通过抑制组蛋白去乙酰化酶和与所述抑制有关的生物过程的治疗用途。

  公开号：

  WO2012136722A1
• 作为产物：
  描述：

  硝基乙酸乙酯 、 (E)-3-(4-羟基苯基)-1-苯基丙-2-烯-1-酮 在 三乙胺 作用下， 反应 4.0h， 生成 ethyl 3-(4-hydroxyphenyl)-2-nitro-5-oxo-5-phenyl-pentanoate
  参考文献：
  名称：

  Hydroxyphenyl pyrrole compounds containing an hydroxamic acid as hdac inhibitors and medicinal applications thereof

  摘要：

  本发明涉及从羟基苯基1H-吡咯环衍生的化合物，其具有以下公式（I）：以及其制备方法，包括相同成分的药物组合物以及用于治疗和/或预防由组蛋白去乙酰化酶介导的病症，如癌症、血液恶性肿瘤、自身免疫疾病、炎症性疾病、中枢神经系统（CNS）疾病如神经退行性疾病和精神障碍、心血管疾病、内分泌和代谢紊乱，通过抑制组蛋白去乙酰化酶和与所述抑制相关的生物过程的治疗用途。

  公开号：

  EP2508510A1

文献信息

• Hydroxyphenyl pyrrole compounds containing an hydroxamic acid as hdac inhibitors and medicinal applications thereof
  申请人：Ikerchem, S.L.

  公开号：EP2508510A1

  公开（公告）日：2012-10-10

  The present invention refers to compounds derived from hydroxyphenyl 1H-pyrrole rings, which have the following formula (I): as well as to the procedure for their preparation, pharmaceutical compositions comprising the same and the use thereof for the treatment and/or prevention of a condition mediated by histone deacetylase such as cancer, hematological malignancies, autoimmune diseases, inflammatory diseases, diseases of the central nervous system (CNS) such as neurodegenerative diseases and psychiatric disorders, cardiovascular diseases, endocrine and metabolic disorders, by inhibiting histone deacetylases and the therapeutic use of biological processes related to the mentioned inhibition.

  本发明涉及从羟基苯基1H-吡咯环衍生的化合物，其具有以下公式（I）：以及其制备方法，包括相同成分的药物组合物以及用于治疗和/或预防由组蛋白去乙酰化酶介导的病症，如癌症、血液恶性肿瘤、自身免疫疾病、炎症性疾病、中枢神经系统（CNS）疾病如神经退行性疾病和精神障碍、心血管疾病、内分泌和代谢紊乱，通过抑制组蛋白去乙酰化酶和与所述抑制相关的生物过程的治疗用途。
• Formation of γ-Oxoacids and 1<i>H</i>-Pyrrol-2(5<i>H</i>)-ones from α,β-Unsaturated Ketones and Ethyl Nitroacetate
  作者：Maialen Aginagalde、Tamara Bello、Carme Masdeu、Yosu Vara、Ana Arrieta、Fernando P. Cossío

  DOI：10.1021/jo101388x

  日期：2010.11.5

  Michael addition of ethyl nitroacetate on α,β-unsaturated ketones followed by Nef oxidation under hydrolytic conditions yields γ-oxoacids instead of the corresponding α,δ-dioxoesters. A concerted decarboxylation step is proposed on the basis of computational results. Finally, conversion of the γ-ketoacids thus prepared into 1H-pyrrol-2(5H)-ones by reaction with primary amines under Paal−Knorr conditions

  在α，β-不饱和酮上迈克尔加成硝基乙酸乙酯，然后在水解条件下进行Nef氧化，生成γ-含氧酸，而不是相应的α，δ-二氧代酯。根据计算结果提出了协同的脱羧步骤。最后，还报道了通过在Paal-Knorr条件下与伯胺反应将如此制备的γ-酮酸转化为1 H-吡咯-2（5 H）-酮。
• A solvent-free synthesis of ethyl 3,5-diaryl-1H-pyrrole-2-carboxylates via triethylphosphite mediated reductive cyclization of ethyl 2-nitro-5-oxo-3,5-diarylpentanoates under microwave irradiation
  作者：Rajni Khajuria、Yeshwinder Saini、Kamal K. Kapoor

  DOI：10.1016/j.tetlet.2013.08.007

  日期：2013.10

  Ethyl 3,5-diaryl-1H-pyrrole-2-carboxylates have been synthesized in good yields from ethyl 2-nitro-5-oxo-3,5-diarylpentanoates by treatment with triethylphosphite under microwave irradiation. The integrity of the mechanism proposed has been augmented by 31P NMR and EIMS experiments.

  通过在微波辐射下用亚磷酸三乙酯处理，由2-硝基-5-氧代-3，5-二芳基戊酸乙酯以高收率合成了3，5-二芳基-1 H-吡咯-2-羧酸乙酯。31 P NMR和EIMS实验提高了所提出机制的完整性。
• HYDROXYPHENYL PYRROLE COMPOUNDS CONTAINING AN HYDROXAMIC ACID AS HDAC INHIBITORS AND MEDICINAL APPLICATIONS THEREOF
  申请人：Cossío Mora Fernando Pedro

  公开号：US20150038545A1

  公开（公告）日：2015-02-05

  The present invention refers to compounds derived from hydroxyphenyl 1H-pyrrole rings, which have the following formula (I): as well as to the procedure for their preparation, pharmaceutical compositions comprising the same and the use thereof for the treatment and/or prevention of a condition mediated by histone deacetylase such as cancer, hematological malignancies, autoimmune diseases, inflammatory diseases, diseases of the central nervous system (CNS) such as neurodegenerative diseases and psychiatric disorders, cardiovascular diseases, endocrine and metabolic disorders, by inhibiting histone deacetylases and the therapeutic use of biological processes related to the mentioned inhibition.

  本发明涉及从羟基苯基1H-吡咯环衍生的化合物，其具有以下式子（I）： 同时，本发明还涉及其制备方法、包含相同化合物的药物组合物以及将其用于治疗和/或预防由组蛋白去乙酰化酶介导的疾病，如癌症、血液恶性肿瘤、自身免疫疾病、炎症性疾病、中枢神经系统（CNS）疾病，如神经退行性疾病和精神障碍、心血管疾病、内分泌和代谢性疾病，通过抑制组蛋白去乙酰化酶和与所述抑制相关的生物过程的治疗用途。
• [EN] HYDROXYPHENYL PYRROLE COMPOUNDS CONTAINING AN HYDROXAMIC ACID AS HDAC INHIBITORS AND MEDICINAL APPLICATIONS THEREOF<br/>[FR] COMPOSÉS HYDROXYPHÉNYL-PYRROLE CONTENANT UN ACIDE HYDROXAMIQUE, UTILISABLES EN TANT QU'INHIBITEURS DE HDAC ET LEURS APPLICATIONS MÉDICALES
  申请人：IKERCHEM S L

  公开号：WO2012136722A1

  公开（公告）日：2012-10-11

  The present invention refers to compounds derived from hydroxyphenyl 1H- pyrrole rings, which have the following formula (I): as well as to the procedure for their preparation, pharmaceutical compositions comprisingthe same and the use thereof for the treatment and/or prevention of a condition mediated by histone deacetylase such as cancer, hematological malignancies, autoimmune diseases, inflammatory diseases, diseases of the central nervous system (CNS) such as neurodegenerative diseases and psychiatric disorders, cardiovascular diseases, endocrine and metabolic disorders, by inhibiting histone deacetylases and the therapeutic use of biological processes related to the mentioned inhibition.

  本发明涉及源自羟基苯基1H-吡咯环的化合物，其具有以下结构式（I）：以及它们的制备方法，包括相同的药物组合物，以及它们用于治疗和/或预防由组蛋白去乙酰化酶介导的疾病，如癌症、血液系统恶性肿瘤、自身免疫疾病、炎症性疾病、中枢神经系统疾病（如神经退行性疾病和精神障碍）、心血管疾病、内分泌和代谢紊乱，通过抑制组蛋白去乙酰化酶和与所述抑制有关的生物过程的治疗用途。